SCHEMBL19582575

SCHEMBL19582575

O=Cc1ccc(C(F)(F)F)c(N2CCCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
ALDH1A3 P47895 6/20 0.58
MAPT P10636 3/20 0.51
NOTUM Q6P988 5/20 0.49
TRIM24 O15164 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
KDM4E B2RXH2 1/20 0.47
KIF11 P52732 1/20 0.45
ALDH3A1 P30838 1/20 0.43
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
MITF O75030 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29417795 1.00 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2ALDH1A3MAPTNOTUM
SCHEMBL19582610 0.89 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2ALDH1A3MAPTNOTUM
SCHEMBL29417741 0.86 ALDH1A3 (0.61) ALDH1A1SMN1; SMN2ALDH1A3NOTUMKDM4E
SCHEMBL19582718 0.86 ALDH1A3 (0.61) ALDH1A1SMN1; SMN2ALDH1A3NOTUMKDM4E
SCHEMBL15264110 0.77 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2ALDH1A3MAPTTRIM24
SCHEMBL30865737 0.77 NOTUM (0.52) ALDH1A1SMN1; SMN2MAPTNOTUMKDM4E
SCHEMBL12684833 0.76 NOTUM (0.51) ALDH1A1MAPTNOTUMFFAR4HTT
SCHEMBL15094164 0.76 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2ALDH1A3MAPTTRIM24
SCHEMBL29728058 0.76 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2ALDH1A3MAPTTRIM24
SCHEMBL1858942 0.75 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2ALDH1A3MAPTTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
CN-110678456-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-05-02 CN disclosed
EP-3630744-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2023-01-25 EP disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
EP-3455226-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2019-03-20 EP disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed
US-20180327416-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2018-11-15 US disclosed
CN-108601769-A Pyrazole compound and its preparation and application 阿比德治疗公司 2018-09-28 CN disclosed
EP-3377060-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2018-09-26 EP disclosed
US-10030020-B2 Spirocycle compounds and methods of making and using same ABIDE THERAPEUTICS, INC. (US) 2018-07-24 US disclosed
WO-2017197192-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
US-20170327500-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL ALDH1A1 2448/4885SMN1; SMN2 3430/4885ALDH1A3 2923/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL ALDH1A1 2448/4885SMN1; SMN2 3430/4885ALDH1A3 2923/4885
US-20180327416-A1 PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME FAAH, FAAH2, MGLL ALDH1A1 1378/4885SMN1; SMN2 3459/4885ALDH1A3 2004/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL ALDH1A1 2260/4885SMN1; SMN2 3564/4885ALDH1A3 2633/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL ALDH1A1 2448/4885SMN1; SMN2 3430/4885ALDH1A3 2923/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL ALDH1A1 2260/4885SMN1; SMN2 3564/4885ALDH1A3 2633/4885
US-20170327500-A1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, ACSL6 ALDH1A1 932/4885SMN1; SMN2 1888/4885ALDH1A3 685/4885
US-10030020-B2 Spirocycle compounds and methods of making and using same ABHD6, ABHD16A, ACSL6 ALDH1A1 932/4885SMN1; SMN2 1888/4885ALDH1A3 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.